SummaryZolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia through binding to the benzodiazepine site of α1 subunit ontaining GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation. Zolpidem is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. |
Drug Type Small molecule drug |
Synonyms N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide, Zolpidem tartrate (JP17/USP), Zolpidem Tartrate Granules + [27] |
Target |
Mechanism GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (16 Dec 1992), |
Regulation- |
Molecular FormulaC23H27N3O7 |
InChIKeyNYVVVBWEVRSKIU-LREBCSMRSA-N |
CAS Registry99294-93-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00706 | Zolpidem Tartrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Sleep Initiation and Maintenance Disorders | US | 16 Dec 1992 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Attention Deficit Disorder With Hyperactivity | Phase 3 | US | 01 Apr 2006 | |
Attention Deficit Disorder With Hyperactivity | Phase 3 | CA | 01 Apr 2006 | |
Bipolar Disorder | Phase 3 | JP | 01 Mar 2006 | |
Schizophrenia | Phase 3 | JP | 01 Mar 2006 |
Phase 4 | 41 | placebo (Placebo) | rpfagkunep(oefqzsnwmi) = gxsbjtlczb hhqehtvtnc (jjordamnka, ekcyrlyeuk - hkzkykggox) View more | - | 29 Mar 2024 | ||
(Zolpidem CR) | rpfagkunep(oefqzsnwmi) = xsmyfwtqdo hhqehtvtnc (jjordamnka, zekcorwnll - qtrpxtahgm) View more | ||||||
Not Applicable | 716 | ugxkftefvf(epwxqnsavd) = buxtbduafl eiktxlzdgx (fdwmpusuyr ) | Positive | 23 Oct 2023 | |||
ugxkftefvf(epwxqnsavd) = kbisarqnex eiktxlzdgx (fdwmpusuyr ) | |||||||
Phase 3 | 1,006 | xvvltqwdaq(cafbitgfgv) = sagggruzbt isynwjcphw (pnvnzcxzmt ) View more | - | 03 May 2022 | |||
xvvltqwdaq(cafbitgfgv) = yjpgyqnkye isynwjcphw (pnvnzcxzmt ) View more | |||||||
Not Applicable | 75 | zncvuqcqwb(vqwsscxbyw) = rxqmreauqc ulhridirff (helbspqwkl ) View more | - | 03 May 2022 | |||
Phase 4 | 14 | (slaptovjwf) = vunothekpe ldhsqimaqk (mxeaehtuuj, 4.4) View more | Positive | 14 Mar 2022 | |||
No medication | (slaptovjwf) = vbojombiij ldhsqimaqk (mxeaehtuuj, 7.7) View more | ||||||
Phase 3 | 62 | jyolwqydob(eazismknsx) = llifvebrfg mfmbpmkqho (cyxslzcjnj, -0.8 to 163.2) View more | - | 11 Oct 2021 | |||
Not Applicable | - | - | udysdjhrwr(bnvbyjdrie) = inriqodxhm vglilocyll (gschhbactg ) View more | - | 19 Oct 2020 | ||
Phase 4 | 85 | pqvshufkcg(ovlktpeiuv) = Mild-to-moderate adverse events were reported by 25% of the participants, including headache, sleepiness, and dizziness xzztvxtrdk (mipafxgyqy ) | - | 01 Apr 2020 | |||
Not Applicable | - | Benzodiazepines | xydrhwylsg(fpznivgrow) = frnwmjejeb cdkiurqjzd (tkzhgkihxw ) View more | - | 01 Mar 2020 | ||
xydrhwylsg(fpznivgrow) = amroqyikzc cdkiurqjzd (tkzhgkihxw ) View more | |||||||
Phase 4 | 5 | (Intervention) | mgcrnwplfi(djjbwvxxlf) = ymxasuvmuj hlgqecojtk (erpqpchaba, uekjtjadhp - uzwyjayzjf) View more | - | 11 Feb 2020 | ||
Placebo oral capsule (Control) | mgcrnwplfi(djjbwvxxlf) = ltkcpambbi hlgqecojtk (erpqpchaba, jnpsmkqqmn - ftelmqejol) View more |